Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations.

Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, Jayakumar P, Gharizadeh B, Ronaghi M, Klein D, Fessel WJ, Shafer RW.

J Virol. 2008 Nov;82(21):10747-55. doi: 10.1128/JVI.01827-07. Epub 2008 Aug 20.

2.

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.

Garcia-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W.

Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13907-12. Epub 2001 Nov 6.

3.

Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naïve Brazilian blood donors.

Sá-Ferreira JA, Brindeiro PA, Chequer-Fernandez S, Tanuri A, Morgado MG.

Transfusion. 2007 Jan;47(1):97-102.

PMID:
17207236
5.

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, Horton J, Ha B, Lanier ER, Elion R; COL40263 study..

J Antimicrob Chemother. 2010 Feb;65(2):307-15. doi: 10.1093/jac/dkp419. Epub 2009 Dec 15.

6.

HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.

Cardoso LP, Queiroz BB, Stefani MM.

J Clin Virol. 2009 Oct;46(2):134-9. doi: 10.1016/j.jcv.2009.07.009. Epub 2009 Aug 13.

PMID:
19682948
7.

Antiretroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotype testing at the Central Public Health Laboratory, São Paulo, Brazil: preliminary results.

Rodrigues R, Vazquez CM, Colares JK, Custodio RM, Bonásser Filho F, Souza Ldo R, Gianna MC, Marques CC, Brígido LF.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):97-102. Epub 2005 Apr 12.

8.

Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid.

Briones C, Pérez-Olmeda M, Rodríguez C, del Romero J, Hertogs K, Soriano V.

J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):145-50.

PMID:
11242181
9.

Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.

Kozal MJ, Chiarella J, St John EP, Moreno EA, Simen BB, Arnold TE, Lataillade M.

Antivir Ther. 2011;16(6):925-9. doi: 10.3851/IMP1851.

PMID:
21900725
10.

Primary HIV-1 drug resistance in the C-terminal domains of viral reverse transcriptase among drug-naïve patients from Southern Brazil.

Santos AF, Silveira J, Muniz CP, Tornatore M, Góes LR, Mendoza-Sassi RA, Martinez AM, Tupinambás U, Greco DB, Soares MA.

J Clin Virol. 2011 Dec;52(4):373-6. doi: 10.1016/j.jcv.2011.09.005. Epub 2011 Oct 4.

11.

High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: study of genotypic resistance.

Pérez-Alvarez L, Carmona R, Muñoz M, Delgado E, Thomson MM, Contreras G, Pedreira JD, Rodríguez Real R, Vázquez de Parga E, Medrano L, Taboada JA, Nájera R; Spanish Group for Antiretroviral Resistance Studies in Galicia..

Antivir Ther. 2003 Aug;8(4):355-60.

PMID:
14518705
12.

Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.

Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.

J Med Virol. 1999 Dec;59(4):507-11.

PMID:
10534734
13.

Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil.

Rodrigues R, Scherer LC, Oliveira CM, Franco HM, Sperhacke RD, Ferreira JL, Castro SM, Stella IM, Brigido LF.

Virus Res. 2006 Mar;116(1-2):201-7. Epub 2005 Dec 5.

PMID:
16332398
14.

Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.

Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.

J Med Virol. 2004 Jul;73(3):350-61.

PMID:
15170628
15.
17.

Evaluation of the LiPA HIV-1 RT assay version 1: comparison of sequence and hybridization based genotyping systems.

Stürmer M, Morgenstern B, Staszewski S, Doerr HW.

J Clin Virol. 2002 Dec;25 Suppl 3:S65-72.

PMID:
12467779
18.

Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals.

Bellecave P, Recordon-Pinson P, Papuchon J, Vandenhende MA, Reigadas S, Tauzin B, Fleury H.

AIDS Res Hum Retroviruses. 2014 Feb;30(2):170-3. doi: 10.1089/AID.2013.0130. Epub 2013 Aug 21.

PMID:
23895115
19.

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K.

Clin Infect Dis. 2005 Mar 1;40(5):728-34. Epub 2005 Feb 4.

PMID:
15714420
20.

'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.

Alteri C, Santoro MM, Abbate I, Rozera G, Bruselles A, Bartolini B, Gori C, Forbici F, Orchi N, Tozzi V, Palamara G, Antinori A, Narciso P, Girardi E, Svicher V, Ceccherini-Silberstein F, Capobianchi MR, Perno CF.

J Antimicrob Chemother. 2011 Nov;66(11):2615-23. doi: 10.1093/jac/dkr354. Epub 2011 Sep 2.

PMID:
21890537

Supplemental Content

Support Center